Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Chris Ehrlich
AddedMar 31, 2024
UpdatedMay 1, 2026
Chris Ehrlich

Chris Ehrlich

Board Member, Satori Pharmaceuticals

Chris Ehrlich's Career

Satori Pharmaceuticals
Satori Pharmaceuticals

Cambridge, MA, US

Board Member· Board
ProLynx
ProLynx

San Francisco, CA, US

Board Member· Board
Solace Pharmaceuticals
Solace Pharmaceuticals

Cambridge, MA, US

Board Member· Board
Follica
Follica

Mendham Borough, NJ, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Chris Ehrlich's Career

Satori Pharmaceuticals
Satori Pharmaceuticals
Public$47.3M302004Cambridge, MA, US
Board Member· Board

Leadership at Satori Pharmaceuticals

Stephen MunizStephen MunizBoard Member
CONNAXISCONNAXISFounder
ProLynx
ProLynx
Seed$2.3M122009San Francisco, CA, US
Board Member· Board

Leadership at ProLynx

Anurag BagariaAnurag BagariaBoard Member
Daniel SantiDaniel SantiFounder
Solace Pharmaceuticals
Solace Pharmaceuticals
Public$15M52006Cambridge, MA, US
Board Member· Board

Leadership at Solace Pharmaceuticals

Daphne ZoharDaphne ZoharBoard Member
Dr Frank Lennox DouglasDr Frank Lennox DouglasBoard Member
Follica
Follica
Series B$24.1M62005Mendham Borough, NJ, US
Board Member· Board

Leadership at Follica

Rox AndersonRox AndersonCo-Founder
George CotsarelisGeorge CotsarelisCo-Founder
Tom WiggansTom WiggansBoard Member
Vera PriceVera PriceCo-Founder
Neal WalkerNeal WalkerBoard Member
William JuWilliam JuBoard Member

Similar to Follica

NutrafolNutrafolNew York City, NY, USHair Growth, Supplementsest. 2014NutrafolNew York City, NY, US · est. 2014

Nutrafol, a leading hair growth supplement brand, offers clinically-backed products targeting root causes of hair health, backed by extensive research.

Series B · $35M304
Pelage PharmaPelage PharmaLos Angeles, CA, USHair Loss TreatmentsPelage PharmaLos Angeles, CA, US

Pelage Pharma: Clinically tested, non-invasive treatments stimulating hair growth for men and women.

Series B · $16.7M7
AmplificaAmplificaSan Diego, CA, USBiopharmaceuticalsest. 2021AmplificaSan Diego, CA, US · est. 2021

Amplifica: A preclinical biopharmaceutical company innovating alopecia treatments.

Series A · $11.8M5
ManeGainManeGainAustin, TX, USHair Products, Hair Therapyest. 2009ManeGainAustin, TX, US · est. 2009

ManeGain, a US start-up, offers non-invasive, chemical-free hair therapy and products for natural hair restoration and prevention of baldness.

Angel · $100k3

Chris Ehrlich's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Chris Ehrlich

Eyal Ben SimonEyal Ben SimonCEO · Phoenix Insurance CompanyCrandell AddingtonCrandell AddingtonCo-Founder · Phoenix BiotechnologyBill CrossmanBill CrossmanCEO · Phoenix PharmaLabsLeo EhrlichLeo EhrlichBoard Member · Innovation PharmaceuticalsLou KostLou KostCo-Founder · Phoenix BiotechnologyRich KleimanRich KleimanCo-Founder · 35V